IRIS
CAVALLONI, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 282
EU - Europa 186
AS - Asia 85
AF - Africa 1
SA - Sud America 1
Totale 555
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 268
IE - Irlanda 113
CN - Cina 70
DE - Germania 24
FI - Finlandia 18
IT - Italia 17
CA - Canada 14
SG - Singapore 12
GB - Regno Unito 4
SE - Svezia 4
BG - Bulgaria 2
FR - Francia 2
IN - India 2
NL - Olanda 2
EC - Ecuador 1
MU - Mauritius 1
QA - Qatar 1
Totale 555
Salva come PNG Salva come JPEG
Città #
Dublin 113
Chandler 66
Beijing 35
Ashburn 26
Helsinki 18
Boardman 17
Lawrence 14
New York 14
Princeton 14
Toronto 13
Medford 11
Shanghai 11
Wilmington 9
Nanjing 6
Seattle 6
Singapore 6
Washington 5
Gallarate 4
Los Angeles 4
Norwalk 4
Falls Church 3
Fano 3
Nanchang 3
Antony 2
Dronten 2
Falkenstein 2
Florence 2
Hangzhou 2
Hebei 2
Jacksonville 2
Jiaxing 2
Milan 2
Sofia 2
Tianjin 2
Woodbridge 2
Berlin 1
Changsha 1
Chesterfield 1
Doha 1
Jiangmen 1
Jinan 1
Leawood 1
Monmouth Junction 1
Ningbo 1
Pavia 1
Pune 1
Quito 1
San Francisco 1
Settimo Torinese 1
Shenyang 1
Totale 444
Salva come PNG Salva come JPEG
Nome #
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 65
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin 56
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. 49
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. 44
Diagnosis and management of prefibrotic myelofibrosis. 44
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. 43
Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib 37
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. 35
Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms 35
Facing erythrocytosis: Results of an international physician survey. 34
Pregnancy outcome and management of 25 pregnancies in women with polycythemia vera. 33
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. 33
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. 33
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients. 28
Eosinophilic dermatosis of hematologic malignancy in patients with chronic lymphocytic leukemia/non-Hodgkin's B lymphoma: a single center prospective clinico-pathological study 5
Totale 574
Salva come PNG Salva come JPEG
Categoria #
all - tutte 3.328
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.328
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202056 0 0 0 0 0 0 2 13 8 19 10 4
2020/202119 4 1 2 3 0 0 1 2 6 0 0 0
2021/202270 0 0 12 2 3 3 1 3 3 1 11 31
2022/2023238 26 12 8 9 15 16 0 14 123 4 10 1
2023/2024127 18 24 8 7 8 37 2 9 3 2 6 3
2024/202537 9 17 7 3 1 0 0 0 0 0 0 0
Totale 574